Largest Genetic Study of Type 1 Diabetes Identifies New Causal Variants and Drug Targets
The largest, most ancestry-diverse study of type 1 diabetes identifying the most likely causal gene variants, possible target genes for drugs and genes that are implicated in other autoimmune diseases with known drug targets has been published.
New Evidence for Biomarkers of Dementia and Value of Aerobic Exercise in Preventing Cognitive...
The researchers looked at whether three specific biomarkers, previously implicated in learning and memory, would increase in older adults following exercise and correlate with cognition and metabolomic markers of brain health.
DeepMind and EMBL Release Extensive, Open Database of Predicted Protein Structures
In a boost for AI-aided biology, the AlphaFold Protein Structure Database, covering around 20,000 human proteins, was launched today by AI-specialists DeepMind in collaboration with the EMBL and is openly available to the scientific community.
T Cells from Previous Coronavirus Infections Lead to Milder COVID-19 Symptoms
A new study suggests that people with COVID-19 may experience milder symptoms because CD8+ T cells “remember” previous encounters with seasonal coronaviruses. In this case, these cells are better equipped to mobilize quickly against an infection with SARS-CoV-2.
Largest Genetic Study of Type 1 Diabetes Identifies New Causal Variants and Drug Targets
The largest, most ancestry-diverse study of type 1 diabetes identifying the most likely causal gene variants, possible target genes for drugs and genes that are implicated in other autoimmune diseases with known drug targets has been published.
Altering Proteins Can Help Limit Mucous Production in Lung Diseases
Researchers at Boston University have discovered a set of signals that control the generation of mucus-secreting goblet cells in the major air passages of the lung that are often found in inflated numbers in lung diseases such as asthma, COPD (Chronic obstructive pulmonary disease), cystic fibrosis, and chronic bronchitis.
Small Sequencer Developer GenapSys Completes $90M Series C Financing
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
The Long and the Short of It: PacBio Strikes $800M Deal to Acquire Omniome
A little less than two years after it's planned combination with short-read sequencing giant Illumina was scuttled, PacBio announced on Tuesday its plans to acquire up-and-coming short-read sequencing company Omniome for approximately $800M.
Identical Mutations Have Organ-Specific Effects According to New Biliary Cancer Study
A recent study showed that the same mutation in precursor cells of the pancreas or the bile duct leads to fundamentally different outcomes thanks to tissue-specific genetic interactions of oncogenes.
COVID-19 May Prompt Strong T Cell Response in Mild Cases with No Detectable Virus-Specific...
The research indicated that T cell responses generated by natural exposure to, or infection with, SARS-CoV-2 may be a significant immune component to the prevention of recurrent episodes of severe disease.
Sussing Out COVID-19 Severity
Can genetic variability explain why some people become seriously ill with COVID-19 while others have only mild illness?
10 Startups to Watch
Early-stage companies advance precision medicine by applying AI, clinical genomics, and other new technologies.
Pushing the Proteomics Envelope
More sensitive technology spurs proteomic and metabolomic biomarker identification, clinical use.
Orchid Launch Stirs Up PRS Debate
The company has begun marketing to consumers its PRS-based preconception test expected to be available later this year.
U.S. Slow to Sequence, Track SARS-CoV-2 Variants
At the end of 2020, the United States ranked 43rd among all countries in sequencing COVID-19 and its variants. New variants are popping up all over the world, causing enormous numbers of new infections in Europe, Canada, India, Brazil, and beyond. Yet here in the United States we are just ramping up our efforts and we continue to fly blind.
